Tysabri Progressive Multifocal Leukoencephalopathy Settlement: Statute of Limitations for Tysabri in Georgia

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Exposure Concerns

For decades, general health and science information has served as the foundation for public understanding of medical risks and patient safety. This legacy framework emphasizes broad awareness of treatment benefits and potential adverse effects, often within the context of informed consent and regulatory oversight. In the domain of mass production, however, the translation of such health information into occupational and legal contexts requires a deliberate shift in focus. The transition from general health literacy to specific exposure concerns becomes necessary when widely used therapeutic agents enter large-scale manufacturing and distribution channels. One such example involves the biologic therapy Tysabri, which has been associated with the risk of progressive multifocal leukoencephalopathy (PML) in certain patient populations. As production volumes increase, the potential for occupational exposure to manufacturing residues or handling protocols raises distinct questions about worker safety and liability. This pivot from patient-oriented health information to industrial exposure scenarios underscores the need for precise legal and regulatory timelines, such as the statute of limitations for claims arising in Georgia.

Bridging Medical Evidence and Legal Timelines

Understanding the medical evidence behind Tysabri-associated PML is essential for evaluating legal claims. Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Georgia who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits for seeking compensation is critical. The prescribing information for Tysabri contains a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, and healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism and Clinical Presentation of PML

PML typically occurs only in immunocompromised individuals and is caused by the JC virus. The clinical presentation can include progressive neurological deficits such as weakness, vision changes, speech difficulties, and cognitive decline. Diagnosis is confirmed through MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The condition usually leads to death or severe disability, making early recognition and cessation of Tysabri essential. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. By blocking lymphocyte migration into the central nervous system, Tysabri reduces immune surveillance, allowing latent JC virus to reactivate and cause infection in the brain. This immunosuppressive effect is compounded in patients with prior immunosuppressant use or prolonged treatment duration.

Legal Considerations and Statute of Limitations in Georgia

From a legal perspective, patients in Georgia who have developed PML after Tysabri use may be eligible for compensation through settlements or litigation. The statute of limitations for product liability claims in Georgia is generally two years from the date the injury was discovered or should have been discovered. For PML, this timeline can be complex because symptoms may develop gradually, and the link to Tysabri may not be immediately apparent. The date of diagnosis or the date when a reasonable person would have connected the neurological symptoms to Tysabri use typically starts the clock. Given the severity of PML, affected patients or their families should consult with an attorney promptly to preserve their legal rights. Settlement considerations for Tysabri-related PML cases often involve evaluating the adequacy of warnings provided to patients and healthcare providers. The prescribing information includes a boxed warning and mandates enrollment in the TOUCH Prescribing Program, which requires patients to read a Medication Guide and understand the risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether these warnings were sufficient to inform patients of the specific risk factors and the need for vigilant monitoring. The timeline between exposure and documented harm is also critical, as PML risk increases with longer treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Cases involving shorter treatment durations may require closer scrutiny of other risk factors. For Georgia residents, the statute of limitations is a strict deadline. Missing the two-year window can bar a claim entirely, regardless of its merits. Therefore, anyone who has experienced neurological symptoms while on Tysabri or who has been diagnosed with PML should seek legal advice immediately. The settlement process may involve negotiation with the manufacturer, Biogen, and could provide compensation for medical expenses, lost income, pain and suffering, and other damages.

Summary and Call to Action

In summary, Tysabri-associated PML is a devastating condition with well-established risk factors and a clear mechanistic basis. Patients in Georgia must be aware of the two-year statute of limitations from the date of discovery of the injury. Prompt legal consultation is essential to evaluate the adequacy of warnings and the specific timeline of exposure and harm. The medical evidence underscores the importance of early detection and cessation of Tysabri at the first sign of PML, but for those already affected, legal recourse may be available within the statutory period.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Georgia?

In Georgia, the statute of limitations for product liability claims is generally two years from the date the injury was discovered or should have been discovered. For PML, this typically starts from the date of diagnosis or when a reasonable person would connect neurological symptoms to Tysabri use. It is crucial to consult an attorney promptly to avoid missing this deadline.

What are the risk factors for developing PML while on Tysabri?

Three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.